MiniMed Group, Inc. (MMED) Stock
4 of the hedge funds AlphaScala tracks reported MMED in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $45.76M.
Which hedge funds own MMED?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 3.06M | $45.76M | +18% |
| Citadel Ken Griffin | 2.87M | $42.84M | +1% |
| Renaissance Technologies Jim Simons (founder) | 88K | $1.32M | NEW |
| Point72 Steve Cohen | 15K | $230.2K | -99% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →MMED price chart
Powered by TradingViewWhat does MiniMed Group, Inc. do?
MiniMed Group, Inc. is a global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for diabetes management. It offers a connected ecosystem of products including automated insulin delivery systems like the MiniMed 780G system with SmartGuard technology for real-time glucose stabilization, InPen smart insulin pens for intelligent dosing support, insulin pumps, continuous glucose monitors, consumables, supplies, related software, and services. These technologies emphasize adaptive, simplified, and reliable care, allowing users to manage diabetes more seamlessly across daily life. Operating in approximately 80 countries, MiniMed Group, Inc. supports diverse preferences such as durable pumps, patch pumps, and app-integrated options, backed by a team of engineers, clinicians, and individuals with diabetes experience. Founded in 1983 and headquartered in Northridge, California, it focuses on relentless innovation in the healthcare sector's medical instruments and supplies industry to enhance outcomes for people requiring intensive insulin therapy.